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Abstract
Background: Recent studies have reported the preventive effects of probiotics on obesity. Among commensal
bacteria, bifidobacteria is one of the most numerous probiotics in the mammalian gut and are a type of lactic acid
bacteria. The aim of this study was to assess the antiobesity and lipid-lowering effects of Bifidobacterium spp.
isolated from healthy Korean on high fat diet-induced obese rats.
Methods: Thirty-six male Sprague-Dawley rats were divided into three groups as follows: (1) SD group, fed
standard diet; (2) HFD group, fed high fat diet; and (3) HFD-LAB group, fed high fat diet supplemented with LAB
supplement (B. pseudocatenulatum SPM 1204, B. longum SPM 1205, and B. longum SPM 1207; 10
8 ~1 0
9 CFU). After
7 weeks, the body, organ, and fat weights, food intake, blood serum levels, fecal LAB counts, and harmful enzyme
activities were measured.
Results: Administration of LAB reduced body and fat weights, blood serum levels (TC, HDL-C, LDL-C, triglyceride,
glucose, leptin, AST, ALT, and lipase levels), and harmful enzyme activities (b-glucosidase, b-glucuronidase, and
tryptophanase), and significantly increased fecal LAB counts.
Conclusion: These data suggest that Bifidobacterium spp. used in this study may have beneficial antiobesity effects.
Background
Obesity, a condition in which an abnormally large
amount of fat is stored in the adipose tissue, resulting in
an increase in body weight, is one of the major public
health problems in the United States and other developed
countries. In general, it is accepted that obesity results
from disequilibrium between energy intake and expendi-
ture [1], and this condition has a great impact on several
metabolic and chronic ailments including heart disease,
cancer, arthritis, obstructive sleep apnea, hypertension,
hyperlipidemia, and type 2 diabetes associated with insu-
lin resistance [2]. To date, pharmacological treatments
do not appear to be effective in producing sustained
long-term weight loss [3]. Therefore, further research is
needed to discover new drug therapies that can be used
to reduce the prevalence of obesity.
Probiotics are defined as viable microbial dietary sup-
plements that exert beneficial effects on host health [4].
Probiotics have attracted public attention because of
their potential effectiveness for both the prevention and
the treatment of immune diseases [5]. In addition, recent
experimental studies have demonstrated the preventive
effects of some bacterial strains on obesity. Among com-
mensal bacteria, bifidobacteria are one of the most
numerous probiotics in the mammalian gut and are a
type of lactic acid bacteria. Bifidobacteria are widely used
and well tolerated. In one study, a strain of Bifidobacter-
ium longum exhibited a more significant effect in lower-
ing serum total cholesterol than a mixed culture of
Streptococcus thermophilus and Lactobacillus delbrueckii
subspecies bulgaricus (SL) both in rats and humans [6].
Another study found that in probiotic treated-mice, Bifi-
dobacterium spp. significantly and positively correlated
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lin-secretion, and normalized inflammatory tone
(decreased endotoxemia, plasma and adipose tissue pro-
inflammatory cytokine) [7]. Finally, VSL no. 3, a mixture
of viable lyophilized bifidobacteria, lactobacilli and Strep-
tococcus thermophilus, improved diet-induced obesity
and its related hepatic steatosis and insulin resistance by
increasing hepatic natural killer T-cells and reducing
inflammatory signaling in mice [8]. These data suggest
that some specific strains of bifidobacteria related to lipid
metabolism and body weight may be potential therapeu-
tic candidates for management of obesity.
In the present study, we used a LAB supplement
of Bifidobacterium pseudocatenulatum SPM 1204
(immuno-enhancement and anti-microbial effects) [9],
Bifidobacterium longum SPM 1205 (inhibitory effect on
harmful enzyme activities of intestinal microflora) [10],
and Bifidobacterium longum SPM 1207 (hypocholestere-
mia effect) [11], and investigated the antiobesity and
lipid-lowering effects of Bifidobacterium spp. on high fat
diet-induced obese rats.
Materials and methods
Bacterial strains used in this study
The culture media and methods used in this study for
the isolation and identification of bacterial strains are
shown in Table 1. For isolation of B. pseudocatenulatum
SPM 1204, B. longum SPM 1205, and B. longum SPM
1207 used in this study, fecal samples from healthy Kor-
eans (20-30 years old) were collected by BBL’s anaerobic
sample collection and transport system to maintain
anaerobic conditions, and were used within 24 h. Fecal
samples were serially diluted 10-fold from 10
-1 to 10
-8,
and 0.1 ml was spread onto selective Blood Liver (BL)
agar medium containing 5% sheep blood. After 48-h
incubation in anaerobic conditions at 37°C, brown or
reddish-brown colonies 2-3 mm in diameter were
selected for further identification [12]. A fructose-6-
phosphate phosphoketolase (F6PPK) test was performed
[13] to ensure that the colonies selected were bifidobac-
teria. To identify the isolated Bifidobacterium spp. at the
species level, 16S rRNA sequencing was performed by
Bioleaders (Daejeon, Korea).
Animals and treatment
A total of 36 male Sprague-Dawley (SD) rats were pur-
chased from Central Lab Animal Inc. (Korea) at three
weeks of age and fed a standard diet (AIN-76A #100000,
Dyets Inc., Bethlehem, PA, USA) for 1 week to stabilize
all metabolic conditions. Food and water were supplied
ad libitum. Each cage contained two rats. The rats were
exposed to a 12-h light/dark cycle and maintained at a
constant temperature of 32 ± 2°C and humidity of 55 ±
5%. All animal experimentation was performed according
to the guidelines for the care and use of laboratory ani-
mals approved by Sahmyook University. The rats were
randomly selected and assigned to three groups (12 rats
per group) according to the type of diet and test-material.
As shown in Table 2, Group 1 SD was fed a standard diet
and PBS (as control); Group 2 HFD was fed a high fat
diet (40% beef tallow modified AIN-76A purified rodent
diet #101556, Dyets Inc., Bethlehem, PA, USA) and PBS;
and Group 3 HFD-LAB was fed a high fat diet and LAB
(B. pseudocatenulatum SPM 1204, B. longum SPM 1205,
and B. longum SPM 1207; 1:1:1 ratio) supplement.
The composition of the experimental diet is shown in
Table 3. All rats were acclimatized to the respective diets
for a week before the experiment started. Then the rats
were orally administered 0.2 ml of PBS or LAB (10
8 ~
10
9 CFU) once a day for 5 weeks. Their body weight and
food intake were measured daily.
Analysis of blood serum and organ weight
At the end of the 7-week experimental period, blood
samples from each rat were collected into tubes using
cardiac puncture. The serum was separated from the
blood by centrifugation at 3,500 rpm for 10 min. The
total cholesterol (TC), high density lipoprotein choles-
terol (HDL-C), low density lipoprotein cholesterol
(LDL-C), triglyceride, glucose, leptin, alanine amino-
transferase (AST), aspartate aminotransferase (ALT)
levels in the serum were analyzed by Korea Animal
Medical Science Institute (Korea). Also, the fat (epididy-
mal and retroperitoneal), liver, spleen and kidney were
removed immediately after the sacrifice and weighed.
Measurement of a-amylase and lipase activities
The activities of a-amylase and lipase were measured
with the a-Amylase Assay Kit (BioAssay Systems,
USA) and Lipase Assay Kit (BioAssay Systems, USA),
respectively.
Table 1 Culture media and methods
Media Main enumerated
microorganisms
Incubation time
(day)
Anaerobic
culture
a
BL agar
medium
b
Predominant anaerobes 3
GAM agar
medium
c
Bifidobacterium spp. 1-2
aCulture media were prepared and dispensed into Petri dishes on a clean
bench. Dishes were stored in a bactron anaerobic chamber (Sheldon
Manufacturing Inc., USA) containing 90% N2,5 %C O 2 and 5% H2 until plating.
A sample of each dilution was plated on each medium in an anaerobic glove
box. Plated dishes were incubated in a bactron anaerobic chamber filled with
CO2 gas. The presence of O2 was monitored with steel wool soaked in
acidified copper sulfate solution.
bBL, Blood Liver (Nissui Pharm. Co. Ltd., Japan).
cGAM, General Anaerobic Medium (Nissui Pharm. Co. Ltd., Japan).
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Fecal samples were collected from the rats weekly to
determine the total LAB counts and harmful enzyme
activities. Fecal samples were taken directly from the
rectum by rectal stimulation and immediately trans-
ferred into sterile tubes and stored at 4°C.
Fecal samples (0.1 g) were suspended in 0.9 ml of 0.1 M
phosphate buffer (pH 6.8 containing 0.5% cysteine) by vor-
texing, and 0.1 ml was then serially diluted 10-fold from
10
-1 to 10
-7. 1 ml was then poured into selective General
Anaerobic Medium (GAM) agar medium (Table 1). After
48 h of incubation under anaerobic conditions, colonies
were counted as Bifidobacterium spp. [10]. The numbers
of colony forming units (CFU) are expressed as log10 CFU
per gram.
Harmful enzyme activities of intestinal microflora
The harmful activities of enzymes such as b-glucosidase,
b-glucuronidase, tryptophanase, and urease of intestinal
microflora related to colon cancer were tested in fecal
samples of rats as previously described [14-16].
Assay of b-glucosidase activity
b-glucosidase activity was assayed in a 2-ml reaction
mixture containing 0.8 ml of 2 mM p-nitrophenyl-b-D-
glucopyranoside and 0.2 ml of enzyme solution (sus-
pended fecal sample). The reaction was incubated for 30
min at 37°C and then stopped by adding 1 ml of 0.5 N
NaOH. The reaction mixture was then centrifuged at
3,000 rpm for 10 min. Enzyme activity was measured by
monitoring absorbance at 405 nm.
Assay of b-glucuronidase activity
b-glucuronidase activity was assayed in a 2-ml reaction
mixture consisting of 0.8 ml of 2 mM p-nitrophenyl-b-
D-glucuronide and 0.2 ml of the enzyme solution. The
reaction was incubated for 30 min at 37°C and then
stopped by adding 1 ml of 0.5 N NaOH. The reaction
mixture was centrifuged at 3,000 rpm for 10 min.
Enzyme activity was measured by monitoring absor-
bance at 405 nm.
Assay of tryptophanase activity
Tryptophanase activity was assayed in a 2.5-ml reaction
mixture consisting of 0.2 ml of complete reagent solu-
tion (2.75 mg of pyridoxal phosphate, 19.6 mg of diso-
dium EDTA dihydrate, and 10 mg of bovine serum
albumin in 100 ml of 0.05 M potassium phosphate buf-
fer, pH 7.5), 0.2 ml of 20 mM tryptophan, and 0.1 ml of
the enzyme solution. The reaction was incubated for 1 h
at 37°C and then stopped by adding 2 ml of color
reagent solution (14.7 g p-dimethylaminobenzaldehyde
in 52 ml H2SO4 and 948 ml 95% ethanol). The reaction
mixture was then centrifug e da t3 , 0 0 0r p mf o r1 0m i n .
Enzyme activity was measured by monitoring absor-
bance at 550 nm.
Assay of urease activity
Urease activity was assayed in a 0.5-ml reaction mixture
consisting of 0.3 ml of urea substrate solution (4 mM
urea in 20 mM sodium phosphate buffer, pH 7.0) and
0 . 1m lo ft h ee n z y m es o l u t i o n .T h er e a c t i o nw a si n c u -
bated for 30 min at 37°C and then stopped by adding
0 . 1m lo f1N( N H 4)2SO4. Phenolnitroprusside reagent
(1 ml) and alkaline hypochlorite reagent (NaClO, 1 ml)
were added to the stopped reaction mixture and incu-
bated for 20 min at 65°C. The reaction mixture was cen-
trifuged at 3,000 rpm for 10 min. Enzyme activity was
measured by monitoring absorbance at 603 nm.
Statistical analysis
Results were expressed as mean ± standard deviation.
Significant differences among groups were determined
using Duncan’s Multiple Range Test (SAS ver. 8.1, SAS
Institute Inc., Cary, NC, USA). Values of P <0 . 0 5w e r e
considered significant.
Table 2 Feeding schedules used in the present study
Groups Rats (n) Food Treatment (oral administration for 5 weeks)
SD 12 Standard Diet 0.2 ml of sterilized PBS
HFD 12 40% High Fat Diet 0.2 ml of sterilized PBS
HFD-LAB 12 40% High Fat Diet 0.2 ml of LAB (10
8 ~10
9 CFU) in sterilized PBS
Table 3 Compositions of experimental diet
Standard Diet High Fat Diet
Ingredients (AIN-76A diet #100000) (AIN-76A diet #101556)
g kcal g kcal
Casein 200 720 200 720
Beef tallow 0 0 400 3600
Methionine 3 12 3 12
Starch 150 540 150 540
Sucrose 500 2000 150 600
Cellulose 50 0 50 0
Corn oil 50 450 0 0
Salt mixture 35 30.8 35 30.8
Vitamin mixture 10 39 10 39
Choline bitartrate 2 0 2 0
Total 1000 3791.8 1000 5541.8
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Body weight, organ weight, fat weight, and food intake
The body weight of all groups was increased every week,
especially that of the HFD fed groups compared to that
of the SD group. The high fat diet promoted a signifi-
cant increase in body weight over the seven-week period
(Figure 1A). Differences in body weight among groups
became noticeable at the fourth week of the diet and
became significant after the seventh week. In the HFD-
LAB group, significant differences occurred after seven
weeks of age. At the end of the experiment, the gain in
body weight was higher in the HFD group than in the
HFD-LAB group (Figure 1B). The mean body weight
increased by 315.86 ± 12.42 g in the SD group, 349.14 ±
29.14 g in the HFD group, and 339.70 ± 26.75 g in the
HFD-LAB group. The average food intake of the HFD-
fed groups was higher than that of the SD group, but
did not differ between the HFD and HFD-LAB groups
(Figure 1C). This indicates that the HFD-fed groups had
similar caloric consumption. This is a clear sign that the
high fat diet induced a profound accumulation of energy
in the form of body fat, including epididymal and retro-
peritoneal fat masses (Table 4). In addition, spleen, kid-
ney, and liver were weighed, but no significant
differences were observed.
Analysis of blood serum levels
The TC, HDL-C, LDL-C, triglyceride, glucose, leptin, AST,
ALT, a-amylase and lipase levels in serum in each group
are summarized in Tables 5 and 6. Compared with the
HFD group, the HFD-LAB group had slightly decreased
TC, HDL-C, LDL-C, triglyceride, glucose, leptin, AST,
ALT, and lipase levels. a-Amylase levels were not
different.
Fecal total LAB counts
Fecal total LAB counts are shown in Figure 2. The fecal
total LAB counts were clearly lower in the HFD-fed
groups than in the SD group over the experimental per-
iod. However, after treatment with LAB, the counts in
the HFD-LAB group were significantly increased com-
pared with those in the HFD group.
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Figure 1 Effects of LAB during experimental periods. (A) Body weight, (B) Weight gain, and (C) Food intake. Data are presented as means
and standard deviation.
An et al. Lipids in Health and Disease 2011, 10:116
http://www.lipidworld.com/content/10/1/116
Page 4 of 8Harmful enzyme activities of intestinal microflora
As shown in Figure 3, the harmful enzyme activities of
intestinal microflora in the HFD-LAB group were
obviously decreased compared with those in the other
groups. After LAB treatment, b-glucosidase, b-glucuro-
nidase, and tryptophanase activities were decreased by
28%, 26% and 10%, respectively. In addition, there was a
statistically significant decrease in b-glucosidase (P =
0.023), b-glucuronidase (P = 0.050), and tryptophanase
(P = 0.002) activities. However, urease activities were
increased.
Discussion
Many studies have reported antiobesity effects of some
bacterial strains such as Lactobacillus spp. and Bifido-
bacterium spp. [17-19,8]. In the present study, we
observed that feeding of a high fat diet for 5 weeks pro-
duced significant increases in body weight, and adminis-
tration of LAB reduced body weight gain and fat weight.
However, there was no significant difference in spleen,
kidney, and liver weights.
Our results demonstrated that the TC, HDL-C, and
LDL-C levels in serum were decreased in the HFD-LAB
group. The reduction of TC or LDL in serum is
reported to lower the risk of coronary heart disease [20].
Recent studies showed that probiotics, including Bifido-
bacterium longum [6], Lactobacillus acidophilus [21],
had hypocholesteremic effects in both rat and human.
The mechanisms involved may be as follows [22-27]: (1)
fermentation products of lactic acid bacteria inhibit cho-
lesterol synthesis enzymes and thus reduce cholesterol
production; (2) the bacteria facilitate the elimination of
cholesterol in feces; (3) the bacteria inhibit the absorp-
tion of cholesterol back into the body by binding with
cholesterol; (4) the bacteria interfere with the recycling
of bile salt (a metabolic product of cholesterol) and
facilitate its elimination, which raises the demand for
bile salt made from cholesterol and thus results in body
cholesterol consumption; and (5) the assimilation of lac-
tic acid. In addition, we found that levels of triglyceride,
glucose, AST, and ALT in serum were reduced in HFD-
LAB group. Similar results have been observed with
some specific probiotics strains [19,8,17].
Leptin has been identified as an antiobesity hormone
that regulates body weight by controlling food intake
and energy expenditure via the hypothalamic-pituitary-
gonadal axis [28-30]. It appears that leptin may be an
important factor in obesity management. Leptin is a 16
KDa secreted protein produced by the ob gene. Adipose
tissue produces leptin and releases it into the blood-
stream. As fat deposits grow, blood leptin levels tend to
increase. Thus, leptin levels are closely related to the
percentage of body fat; markedly higher serum leptin
levels have been found in obese individuals compared
with non-obese individuals [31,32]. In contrast, leptin
levels are severely reduced in underweight individuals
compared with normal weight individuals [33,34]. In the
present study, leptin levels were higher in the HFD-fed
Table 4 Weights of body, fat, spleen, kidney, and liver
SD HFD HFD-LAB
Body weight (g) 381.00 ± 11.95
B 413.86 ± 30.28
A 402.20 ± 29.23
AB
Fat weight (g) (epididymal + retroperitoneal) 13.94 ± 2.66
B 20.94 ± 4.08
A 18.47 ± 2.02
A
Fat pad weight (g/100 g body weight) 3.63 ± 0.65
B 5.11 ± 0.60
A 4.83 ± 0.40
A
Spleen (g) 0.66 ± 0.03 0.60 ± 0.07 0.64 ± 0.10
Kidney (g) 2.59 ± 0.15 2.60 ± 0.18 2.61 ± 0.08
Liver (g) 18.47 ± 1.95
AB 20.04 ± 2.27
A 17.59 ± 2.33
B
Each value provided is the mean ± standard deviation. Values of each group with the same letters for each serological factor were not significantly different (P <
0.05).
Table 5 Serum levels of cholesterol, triglyceride, glucose, leptin, AST, and ALT
SD HFD HFD-LAB
TC (mg/dl) 88.20 ± 12.24 92.20 ± 11.02 89.70 ± 17.33
HDL-C (mg/dl) 54.40 ± 9.25
A 47.40 ± 7.55
AB 46.09 ± 7.25
B
LDL-C (mg/dl) 19.15 ± 2.96
A 16.75 ± 3.27
AB 15.22 ± 4.40
B
Triglyceride (mg/dl) 146.18 ± 33.76
B 262.40 ± 110.75
A 246.70 ± 74.18
A
Glucose (mg/dl) 230.40 ± 41.31
AB 236.50 ± 35.53
A 200.36 ± 37.09
B
Leptin (pg/ml) 433.88 ± 117.15
B 575.68 ± 149.86
A 538.08 ± 158.12
AB
AST (U/L) 98.50 ± 33.78
AB 111.00 ± 13.39
A 84.45 ± 13.77
B
ALT (U/L) 38.00 ± 5.25
B 65.00 ± 8.16
A 62.70 ± 4.35
A
Each value provided is the mean ± standard deviation. Values of each group with the same letters for each serological factor were not significantly different (P <
0.05).
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HFD-LAB group than in the HFD group. Similar effects
have been observed in other studies using mouse [17]
and human [32]. The results of these studies suggest
that reductions in fat mass and body weight are asso-
ciated with a reduction in leptin.
a-Amylase, a digestive enzyme secreted from the pan-
creas and salivary gland, is involved in important biolo-
gical processes such as digestion of carbohydrates. Many
crude drugs inhibit a-amylase activity [35]. Natural a-
amylase inhibitors are beneficial in reducing post-pran-
dial hyperglycemia by slowing down the digestion of
carbohydrates and, consequently, the absorption of glu-
cose. Reducing post-prandial hyperglycemia prevent glu-
cose uptake into adipose tissue to inhibit synthesis and
accumulation of triacylglycerol [36]. On the other hand,
it is well known that dietary lipid is not directly
absorbed from the intestine unless it has been subjected
to the action of pancreatic lipase. The two main pro-
ducts formed by the hydrolysis of pancreatic lipase are
fatty acid and 2-monoacylglycerol. Inhibition of these
digestive enzymes is therefore beneficial in the treat-
ment of obesity [37]. Our results showed that lipase
levels were slightly decreased in the HFD-LAB group,
whereas a-amylase levels were increased. That is, LAB
had an inhibitory effect on lipase.
In our study, fecal LAB counts were obviously
decreased in the HFD-fed groups compared with those in
the SD group. Similarly, Cani et al. [38] demonstrated
that a high fat diet changed the intestinal microbiota
composition; in particular, the number of Bifidobacter-
ium spp. was reduced. Kalliomaki et al. [39] also observed
that fecal Bifidobacterium spp. counts were higher in
children who remained at normal weight at the age of
seven, while this was not the case in overweight children.
After treatment with LAB, we found that the LAB counts
in the HFD-LAB group were significantly increased com-
pared with those in the HFD group. This result means
that LAB survive passage through the upper-gastrointest-
inal tract after oral feeding, and ingested LAB affect the
intestinal environment to favor LAB colonization [40].
Several studies have shown that these specific bacteria
reduce the intestinal endotoxin levels and improve
mucosal barrier function [41-43]. Furthermore, LAB
have anti-tumor effects and block harmful intestinal
enzyme activities, a recognized risk factor for colon can-
cer [44,45]. The results of the present study showed the
harmful enzyme activities of intestinal microflora in the
5.0
6.0
7.0
8.0
9.0
10.0
123456
Weeks
L
A
B
 
c
o
u
n
t
s
 
(
l
o
g
 
C
F
U
/
g
)
SD HFD HFD-LAB
QQQG
QG
QG
Figure 2 Changes of total LAB counts during experimental periods. Data are presented as means and standard deviation. *P <0 . 0 5a n d
***P < 0.001 significantly different compared with HFD group.
Table 6 Serum levels of a-amylase and lipase
SD HFD HFD-LAB
a-amylase (U/L) 182.36 ± 10.73 172.33 ± 12.51 191.57 ± 16.16
Lipase (U/L) 91.10 ± 21.38
B 224.25 ± 33.21
A 216.52 ± 22.52
A
Each value provided is the mean ± standard deviation. Values of each group
with the same letters for each serological factor were not significantly
different (P < 0.05).
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those in the other groups; in particular, the activities of
b-glucosidase, b-glucuronidase, and tryptophanase were
significantly decreased.
Conclusion
In conclusion, we suggest that the LAB supplement (B.
pseudocatenulatum SPM 1204, B. longum SPM 1205, B.
longum SPM 1207) used in this study may have benefi-
cial antiobesity effects. Further clinical trials to confirm
these effects should therefore be conducted.
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